Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus

Causes of Death and One-Year Follow-up

Tsu F. Yeh, Amin Thalji, Rosita S. Pildes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

Original languageEnglish
Pages (from-to)803-807
Number of pages5
JournalAmerican Journal of Diseases of Children
Volume136
Issue number9
DOIs
Publication statusPublished - Jan 1 1982
Externally publishedYes

Fingerprint

Patent Ductus Arteriosus
Premature Infants
Indomethacin
Cause of Death
Kernicterus
Necrotizing Enterocolitis
Therapeutics
Hydrocephalus
Double-Blind Method
Respiratory Tract Infections
Electroencephalography
Autopsy
Sepsis
Pneumonia
Hemorrhage
Kidney
Control Groups
Brain
Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus : Causes of Death and One-Year Follow-up. / Yeh, Tsu F.; Thalji, Amin; Pildes, Rosita S.

In: American Journal of Diseases of Children, Vol. 136, No. 9, 01.01.1982, p. 803-807.

Research output: Contribution to journalArticle

@article{0fd3309dfd7640d38238c8645d7224a4,
title = "Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus: Causes of Death and One-Year Follow-up",
abstract = "Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24{\%}) and three in the indomethacin group (23{\%}) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.",
author = "Yeh, {Tsu F.} and Amin Thalji and Pildes, {Rosita S.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1001/archpedi.1982.03970450045012",
language = "English",
volume = "136",
pages = "803--807",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus

T2 - Causes of Death and One-Year Follow-up

AU - Yeh, Tsu F.

AU - Thalji, Amin

AU - Pildes, Rosita S.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

AB - Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

UR - http://www.scopus.com/inward/record.url?scp=0019992893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019992893&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1982.03970450045012

DO - 10.1001/archpedi.1982.03970450045012

M3 - Article

VL - 136

SP - 803

EP - 807

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 9

ER -